News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
205,640 Results
Type
Article (4710)
Company Profile (94)
Press Release (200836)
Section
Business (62923)
Career Advice (97)
Deals (11931)
Drug Delivery (7)
Drug Development (34425)
Employer Resources (12)
FDA (3872)
Job Trends (3784)
News (113075)
Policy (8388)
Tag
2024 BioCapital Digital (3)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (2)
2024 Biotech Bay Standard (4)
2024 Biotech Beach Digital (2)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (1)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (3)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (223)
Accelerated approval (1)
Allergies (30)
Alliances (16768)
ALS (33)
Alzheimer's disease (395)
Antibody-drug conjugate (ADC) (40)
Approvals (3937)
Artificial intelligence (45)
Autoimmune disease (7)
Automation (1)
Bankruptcy (56)
Best Places to Work (3232)
BIOSECURE Act (2)
Biosimilars (37)
Biotechnology (67)
Bladder cancer (33)
Brain cancer (13)
Breast cancer (72)
Cancer (748)
Cardiovascular disease (36)
Career advice (88)
Career pathing (2)
CAR-T (45)
Cell therapy (118)
Cervical cancer (3)
Clinical research (29678)
Collaboration (275)
Compensation (283)
Complete response letters (4)
COVID-19 (495)
CRISPR (5)
C-suite (96)
Cystic fibrosis (21)
Data (883)
Depression (12)
Diabetes (65)
Diagnostics (891)
Digital health (1)
Diversity, equity & inclusion (2)
Drug discovery (32)
Drug pricing (2)
Drug shortages (5)
Duchenne muscular dystrophy (26)
Earnings (26648)
Editorial (2)
Employer branding (1)
Employer resources (11)
Events (36452)
Executive appointments (282)
FDA (4295)
Featured Employer (17)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (1)
Funding (192)
Gene editing (13)
Generative AI (1)
Gene therapy (51)
GLP-1 (162)
Government (576)
Grass and pollen (1)
Guidances (15)
Healthcare (2619)
Huntington's disease (5)
IgA nephropathy (11)
Immunology and inflammation (22)
Indications (13)
Infectious disease (522)
Inflammatory bowel disease (50)
Influenza (11)
Intellectual property (39)
Interviews (12)
IPO (6321)
IRA (2)
Job creations (712)
Job search strategy (82)
Kidney cancer (5)
Layoffs (36)
Legal (1518)
Liver cancer (27)
Lung cancer (120)
Lymphoma (62)
Management (4)
Manufacturing (97)
MASH (35)
Medical device (1362)
Medtech (1363)
Mergers & acquisitions (5882)
Metabolic disorders (189)
Multiple sclerosis (29)
NASH (7)
Neurodegenerative disease (21)
Neuropsychiatric disorders (2)
Neuroscience (568)
NextGen: Class of 2025 (883)
Non-profit (234)
Northern California (1115)
Now hiring (3)
Obesity (86)
Opinion (16)
Ovarian cancer (25)
Pain (24)
Pancreatic cancer (22)
Parkinson's disease (47)
Partnered (2)
Patents (73)
Patient recruitment (42)
Peanut (15)
People (18391)
Pharmaceutical (34)
Phase I (8653)
Phase II (13314)
Phase III (9945)
Pipeline (489)
Policy (7)
Postmarket research (673)
Preclinical (3197)
Press Release (13)
Prostate cancer (26)
Psychedelics (4)
Radiopharmaceuticals (107)
Rare diseases (95)
Real estate (1406)
Recruiting (7)
Regulatory (6909)
Reports (13)
Research institute (260)
Resumes & cover letters (6)
RSV (5)
Schizophrenia (41)
Series A (32)
Series B (21)
Service/supplier (2)
Sickle cell disease (5)
Southern California (895)
Spinal muscular atrophy (40)
Sponsored (1)
Startups (1020)
State (2)
Stomach cancer (1)
Supply chain (15)
Tariffs (3)
United States (8234)
Vaccines (106)
Venture capitalists (3)
Weight loss (16)
Women's health (2)
Date
Today (60)
Last 7 days (300)
Last 30 days (921)
Last 365 days (12024)
2025 (3780)
2024 (12961)
2023 (14923)
2022 (19539)
2021 (20761)
2020 (18114)
2019 (11634)
2018 (8461)
2017 (10548)
2016 (8925)
2015 (11495)
2014 (8723)
2013 (6635)
2012 (6715)
2011 (6795)
2010 (6656)
Location
Africa (135)
Alabama (15)
Arizona (27)
Arkansas (2)
Asia (27199)
Australia (3402)
California (2325)
Canada (627)
China (367)
Colorado (65)
Connecticut (83)
Delaware (77)
Europe (30976)
Florida (281)
Georgia (71)
Idaho (3)
Illinois (97)
India (11)
Indiana (66)
Iowa (2)
Japan (106)
Kansas (57)
Kentucky (7)
Louisiana (1)
Maine (6)
Maryland (245)
Massachusetts (1829)
Michigan (31)
Minnesota (100)
Missouri (13)
Nebraska (5)
Nevada (3)
New Hampshire (2)
New Jersey (891)
New Mexico (4)
New York (813)
North Carolina (341)
Northern California (1115)
Ohio (57)
Oklahoma (3)
Oregon (10)
Pennsylvania (399)
Puerto Rico (1)
Rhode Island (2)
South America (199)
Southern California (895)
Tennessee (8)
Texas (221)
Utah (47)
Virginia (67)
Washington D.C. (10)
Washington State (123)
Wisconsin (12)
205,640 Results for "intas biopharmaceuticals ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
December 3, 2024
·
15 min read
Press Releases
Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth
December 3, 2024
·
8 min read
Press Releases
Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), in the United States of America
February 10, 2025
·
6 min read
Press Releases
BioCity Biopharmaceutics Co., Ltd. Announces Clinical Collaboration to Evaluate BC3195 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors
March 13, 2025
·
3 min read
Press Releases
Hanx Biopharmaceuticals, Ltd. Announces First Patient Dosing in First-in-Human Phase 1 Clinical Trial of HX044
January 2, 2025
·
2 min read
Press Releases
Kairos Pharma Ltd. Provides Letter to Stockholders
April 24, 2025
·
5 min read
Press Releases
Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction
Antev Shareholders to Receive Aggregate ~19% Equity Stake in Medicus, Plus US$65 Million in Contingent Payments
April 28, 2025
·
10 min read
Press Releases
Tenpoint Therapeutics Ltd. to Participate at Citi Biotech Private Access Day
April 23, 2025
·
1 min read
Press Releases
Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
April 28, 2025
·
3 min read
Business
Henlius Deepens Collaboration with Intas to bring Henlius’ Novel anti-PD-1 mAb Serplulimab to Europe and India
Shanghai Henlius Biotech, Inc. (2696.HK) has entered into an exclusive license agreement with Intas Pharmaceuticals Limited (“Intas”) for the development and commercialisation in Europe and India for several indications including ES-SCLC, and specific formulation of HANSIZHUANG (serplulimab injection), Henlius’ novel anti-PD-1 mAb.
October 27, 2023
·
10 min read
1 of 20,564
Next
